2025-06-18-世界卫生组织-INN_Stem_Book_Addendum_202506-2024_5页_71kb

INN Addendum Summary

This document updates the INN stems based on changes from the 2024 guidelines, covering new stem selections, modifications to stem definitions, and the adoption of a new monoclonal antibody naming convention. The copyright and distribution rights belong to WHO.

Newly Selected Stems (Cumulative List Since 2024 Publication)

• -alkib Stem Group: Includes inhibitors for ALK receptors, such as compounds like alectinib derivatives (e.g., alpinib, brgatinib).
• -ampator Stem Group: For AMPA receptor modulators, including substances like farampator and mibampator, used in neurological or therapeutic contexts.
• -circin Stem Group: Covers CC chemokine receptor antagonists, targeting inflammatory pathways with names like ilacirnon.
• -deferrum Stem Group: For iron chelating agents, such as deferiprone and deferitrin derivatives, used in clinical scenarios like iron overload treatment.
• -menib Stem Group: Targets menin interaction inhibitors for cancer therapy, including balomenib and revumenib.
• -inosine Stem Group: For purine nucleoside analogues with antiviral or antineoplastic uses, e.g., didanosine and adenosine derivatives.
• -protaphin Stem Group: Inhibits HPTP enzymes, with compounds like batoprotafib relevant to enzyme regulation.
• -rogant Stem Group: Deals with RORγ antagonists and inverse agonists, including bevurogant for inflammatory conditions.
• -statin Stem Group: Specifically for aldosterone and cortisol synthesis inhibitors, e.g., osilodrostat.
• -tide Stem Group: Covers peptide-based INNs like amylin receptor agonists (e.g., amlintide) or PSMA-binding peptides.
• -tinib Stem Group: For tyrosine kinase inhibitors, including fibroblast growth factor receptor inhibitors like dabogratinib.
• -turev Stem Group: Under advanced therapy, for oncolytic viruses, such as canerpaturev in cancer treatments.
• -vatein Stem Group: For protein vaccines related to coronaviruses, e.g., carocovatein for immunization.
• -vir Stem Group: Focuses on antiviral agents like trelvir 3CL protease inhibitors.
• General Note: Many stems come under categories like (c), covering various therapeutic areas like oncology or infectious diseases.

Updates to Stem Definitions

• -cianine: Now includes cyanine dyes and derivatives for diagnostic imaging agents, expanding from the original indocyanine fluorescence dye group.
• -phylline: Replaced N-methylated xanthine derivatives with N-alkylated xanthine derivatives, broadening applicability.
• -ilide: Category remains as class III antiarrhythmics sematilide derivatives, but referenced refinements.
• -kalim: Definition unchanged; potassium channel activators for antihypertensive uses.
• -kinra: Now explicitly referred to as interleukin receptor antagonists and interleukin inhibitors, enhancing specificity.
• -nidine: Altered from antihypertensives to α-adrenoreceptor agonists, affecting drug classification.
• -sartan/-dirsen: Updated for splice-switching oligonucleotides in muscular dystrophies.
• -tant/-netant: Neurokinin NK3 or dual receptor antagonists, impacting pain or inflammatory treatments.
• -tirom(e): Thyromimetic derivatives for antihyperlipidemic use, with a caution for terminology in future naming.
• -gromab: Designation changed for monoclonal antibodies targeting growth factors in specific contexts.

Other Changes and Notes

• A new nomenclature for monoclonal antibodies was adopted at the INN Consultation in 2021, providing a standardized approach for future naming; details available at: https://cdn.who.int/media/.../new_mab_nomenclature_2021.pdf.
• This addendum is cumulative and may include corrections to existing stems, ensuring alignment with current therapeutic landscapes.
• For comprehensive details on the stemmed compounds and references, consult the full document linked to ISBN 9-789240-099388.